| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Andrea Zangara | |
| P2860 | cites work | A new and rapid colorimetric determination of acetylcholinesterase activity | Q26778487 |
| Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A | Q27734318 | ||
| Molecular mechanisms of calcium-dependent excitotoxicity | Q28141475 | ||
| Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease | Q28142745 | ||
| Atomic Structure of Acetylcholinesterase from Torpedo californica : A Prototypic Acetylcholine-Binding Protein | Q28247386 | ||
| Old Chinese herbal medicine used for fever yields possible new Alzheimer disease therapy | Q28304777 | ||
| New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease | Q31643664 | ||
| Galantamine: a review of its use in Alzheimer's disease | Q31754077 | ||
| AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease | Q34147757 | ||
| Neuroprotection and neurodegenerative disease | Q34465893 | ||
| Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. | Q34502056 | ||
| The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. | Q34511298 | ||
| Review of the value of huperzine as pretreatment of organophosphate poisoning | Q34775146 | ||
| Non-cholinergic strategies for treating and preventing Alzheimer's disease | Q34991505 | ||
| Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases | Q36278346 | ||
| The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory | Q36489645 | ||
| Calcium and excitotoxic neuronal injury. | Q40586805 | ||
| Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo | Q40779657 | ||
| Huperzine A protects rat pheochromocytoma cells against oxygen-glucose deprivation | Q40793410 | ||
| Effect of Huperzine A, a novel acetylcholinesterase inhibitor, on radial maze performance in rats | Q42277816 | ||
| Biochemical Assessment of Serotonergic and Cholinergic Dysfunction and Cerebral Atrophy in Alzheimer's Disease | Q42453090 | ||
| Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine | Q42540971 | ||
| Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells | Q43507307 | ||
| Mechanism of inhibition of cholinesterases by huperzine A | Q43712194 | ||
| Effect of huperzine A on working memory in reserpine- or yohimbine-treated monkeys | Q43832376 | ||
| Stereoselectivities of enantiomers of huperzine A in protection against beta-amyloid(25-35)-induced injury in PC12 and NG108-15 cells and cholinesterase inhibition in mice | Q43832603 | ||
| The NMDA receptor ion channel: a site for binding of Huperzine A. | Q43938349 | ||
| Interaction of a new potent anticholinesterasic compound (+/-)huprine X with muscarinic receptors in rat brain | Q44014503 | ||
| Subchronic administration of pyridostigmine or huperzine to primates: compared efficacy against soman toxicity | Q44098520 | ||
| Changes in brain cholinesterases in senile dementia of Alzheimer type | Q48176243 | ||
| Huperzine A as a pretreatment candidate drug against nerve agent toxicity | Q48207166 | ||
| The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease | Q48391011 | ||
| Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities | Q48445846 | ||
| Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia | Q48493014 | ||
| Butyrylcholinesterase in the life cycle of amyloid plaques | Q48582974 | ||
| Effects of chronic administration of huperzine A on memory in guinea pigs | Q48684961 | ||
| Acute and chronic studies with the anticholinesterase Huperzine A: effect on central nervous system cholinergic parameters | Q48694658 | ||
| The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers | Q48707123 | ||
| Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate | Q48768220 | ||
| Prediction of the binding sites of huperzine A in acetylcholinesterase by docking studies | Q49177167 | ||
| Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. | Q50869517 | ||
| Cholinesterase Inhibition in the Scopolamine Model of Dementia | Q52103175 | ||
| Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. | Q52167583 | ||
| Huperzine A ameliorates the spatial working memory impairments induced by AF64A. | Q52204749 | ||
| Huperzine A – a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease | Q53182659 | ||
| Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. | Q53204206 | ||
| Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors | Q59215345 | ||
| Effect of huperzine A, a new cholinesterase inhibitor, on the central cholinergic system of the rat | Q69387060 | ||
| The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat | Q69419742 | ||
| Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines | Q71588174 | ||
| Efficacy of huperzine in preventing soman-induced seizures, neuropathological changes and lethality | Q73816516 | ||
| Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury | Q74218368 | ||
| Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells | Q74425256 | ||
| The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity | Q105368948 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | huperzine A | Q425198 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 675-86 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Pharmacology, Biochemistry and Behavior | Q15716554 |
| P1476 | title | The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease | |
| P478 | volume | 75 |
| Q40167513 | 3D-QSAR analysis of a new type of acetylcholinesterase inhibitors |
| Q47887706 | A randomized, double-blind, placebo controlled, parallel group, efficacy study of alpha BRAIN® administered orally |
| Q50192690 | A review of the use of pteridophytes for treating human ailments |
| Q46477020 | Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment Ameliorate Acetaminophen-Induced Liver Injury in Mice via Central Cholinergic System Regulation |
| Q64974855 | Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities. |
| Q36565002 | Advances in toxicology and medical treatment of chemical warfare nerve agents |
| Q37427017 | Botanicals and herbs: a traditional approach to treating epilepsy |
| Q35944934 | Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway |
| Q83195330 | Chiral separation of Huperzine A using CE - method validation and application in pharmaceutical formulations |
| Q86409209 | Combined use of cyclofructans and an amino acid ester-based ionic liquid for the enantioseparation of huperzine A and coumarin derivatives in CE |
| Q115965993 | Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer's Disease |
| Q48301613 | Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats |
| Q89674964 | Effects of huperzine A on hippocampal inflammatory response and neurotrophic factors in aged rats after anesthesia |
| Q46658406 | Enzyme inhibitor screening by electrospray mass spectrometry with immobilized enzyme on magnetic silica microspheres |
| Q92964504 | Exploring the efficacy of natural products in alleviating Alzheimer's disease |
| Q38169121 | Heathcock-inspired strategies for the synthesis of fawcettimine-type Lycopodium alkaloids |
| Q34033004 | High throughput enzyme inhibitor screening by functionalized magnetic carbonaceous microspheres and graphene oxide-based MALDI-TOF-MS. |
| Q37342533 | Huperzine A Provides Robust and Sustained Protection against Induced Seizures in Scn1a Mutant Mice |
| Q24202101 | Huperzine A for mild cognitive impairment |
| Q24234330 | Huperzine A for mild cognitive impairment |
| Q34063312 | Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? |
| Q37594755 | Huperzine a in the treatment of Alzheimer's disease and vascular dementia: a meta-analysis |
| Q37125488 | Impaired cognition and attention in adults: pharmacological management strategies |
| Q82605473 | Isolation and characterization of endophytic huperzine A-producing fungi from Huperzia serrata |
| Q38162960 | Nature as a source of metabolites with cholinesterase-inhibitory activity: an approach to Alzheimer's disease treatment. |
| Q37638688 | New and investigational antiepileptic drugs |
| Q36349629 | Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease |
| Q28273051 | Pharmacokinetics of huperzine A following oral administration to human volunteers |
| Q26777933 | Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease |
| Q36163359 | Regulation of neuroinflammation by herbal medicine and its implications for neurodegenerative diseases. A focus on traditional medicines and flavonoids |
| Q38519803 | Review of the use of botanicals for epilepsy in complementary medical systems--Traditional Chinese Medicine |
| Q37400454 | Role of huperzine a in the treatment of Alzheimer's disease |
| Q36749831 | Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder |
| Q43275974 | Study of acetylcholinesterase inhibitors using CE with contactless conductivity detection |
| Q36709537 | Targeting acetylcholinesterase to treat neurodegeneration |
| Q34775101 | The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques |
| Q34463098 | Utility of nutraceutical products marketed for cognitive and memory enhancement |
| Q37480076 | Vascular Contributions to Cognitive Impairment and Treatments with Traditional Chinese Medicine. |
| Q37563268 | Whole-Genome Shotgun Assembly and Analysis of the Genome of Shiraia sp. Strain Slf14, a Novel Endophytic Fungus Producing Huperzine A and Hypocrellin A. |
Search more.